Mallinckrodt Inc

Mallinckrodt — Corporate Update (March 2021)

20 slides from Mallinckrodt's corporate update, Mar 10, 2021

  1. Slide 1: Mallinckrodt Pharmaceuticals: Preliminary 2021 Strategic Plan

    Exhibit 99.3 SUBJECT TO FRE 408, STATE LAW EQUIVALENTS Mallinckrodt Pharmaceuticals: Preliminary 2021 Strategic Plan March 2021Exhibit 99.3 SUBJECT TO FRE 408, STATE LAW EQUIVALENTS Mallinckrodt Pharmaceuticals: Preliminary 2021 Strategic Plan March 2021

  2. Slide 2: Disclaimers (1 / 2) Cautionary Statements Related to Forward-Looking Statements

    SUBJECT TO FRE 408, STATE LAW EQUIVALENTS Disclaimers (1 / 2) Cautionary Statements Related to Forward-Looking Statements Statements in this document that are not strictly historical, including statements regarding future financial condition and operating results, legal, economic, business, competit

  3. Slide 3: Disclaimers (1 / 2) Cautionary Statements (cont'd)

    SUBJECT TO FRE 408, STATE LAW EQUIVALENTS Disclaimers (1 / 2) Cautionary Statements Related to Forward-Looking Statements (cont’d) Mallinckrodt’s ability to receive procurement and production quotas granted by the U.S. Drug Enforcement Administration; complex manufacturing processes; conducting busi

  4. Slide 4: Disclaimers (2 / 2) Non-GAAP Financial Measures

    SUBJECT TO FRE 408, STATE LAW EQUIVALENTS Disclaimers (2 / 2) Non-GAAP Financial Measures When the Company provides its expectation for adjusted net sales, adjusted EBITDA, adjusted operating cash flow and free cash flow on a forward-looking basis, a reconciliation of the differences between the non

  5. Slide 5: Better positioned to be an innovation-driven biopharmaceutical growth company

    SUBJECT TO FRE 408, STATE LAW EQUIVALENTS The Company will be better positioned to achieve its vision of being an innovation-driven biopharmaceutical growth company Company Vision …focused on improving …in two primary Innovation-driven outcomes for …adding value through brands segments – biopharmace

  6. Slide 6: Executing this strategy involves three phases, optimizing towards Critical Care

    SUBJECT TO FRE 408, STATE LAW EQUIVALENTS Executing this strategy involves three phases, optimizing the Company’s future operating model towards Critical Care 2021 2022 2023 2024 2025 Restructuring Post-Emergence Longer Term ► Maximize EBITDA and align ► Ensure compelling growth story by ► Position

  7. Slide 7: Specialty Brands Strategic Outlook

    SUBJECT TO FRE 408, STATE LAW EQUIVALENTS Specialty Brands Strategic Outlook › An optimized resource allocation toward Critical Care, prioritizing buy-ups and lifecycle management, is supported by a compelling strategic rationale that will allow the Company to capitalize on demonstrated and distinct

  8. Slide 8: Critical Care has strong commercialized and existing pipeline options

    SUBJECT TO FRE 408, STATE LAW EQUIVALENTS Critical Care has strong commercialized and existing pipeline options Projected Brands Pipeline at Emergence TA Preclinical Phase 1 Phase 2 Phase 3 Commercialized Nitric Oxide INOmax INOmax 4 3 TBI , Cardio HRF EVOLVE device Therakos INOmax SOLAS Japan Thera

  9. Slide 9: Work is ongoing to align capabilities with the Critical Care focus

    SUBJECT TO FRE 408, STATE LAW EQUIVALENTS Work is ongoing across the organization to align our capabilities with the Critical Care strategic focus Targeted Savings Commentary The Company is enacting approximately $85 million of targeted › Commercial Initiatives annualized cost savings across SG&A an

  10. Slide 10: These cost savings support the focus on Critical Care opportunities

    SUBJECT TO FRE 408, STATE LAW EQUIVALENTS These cost savings support the Company’s focus on Critical Care opportunities › The Company’s targeted savings initiatives across cost areas and functions is expected to be implemented in the near term, yielding annual run rate savings of $85 million in 2025

  11. Slide 11: Specialty Generics Strategic Outlook

    SUBJECT TO FRE 408, STATE LAW EQUIVALENTS Specialty Generics Strategic Outlook Specialty Generics continues to deliver stable cash flows amidst near-term headwinds and make the proper strategic investments required to drive mid-to-longer term growth › 2020 SpecGx expected operating profit is in line

  12. Slide 12: Specialty Generics' strategy focuses on maximizing value of the business

    SUBJECT TO FRE 408, STATE LAW EQUIVALENTS Specialty Generics’ strategy focuses on maximizing value of the business to maintain range of strategic options › Maintain market share in existing › Advance current ANDA pipeline of oral segment areas (opioids, ADHD, solid and complex formulations addiction

  13. Slide 13: Consolidated Revenue and EBITDA Summary

    SUBJECT TO FRE 408, STATE LAW EQUIVALENTS Consolidated Revenue and EBITDA Summary (1) • Projected revenue and EBITDA grow in the outer years as the Company emerges from Chapter 11 and optimizes its development strategy on Critical Care opportunities to drive long-term growth • Overall assumptions re

  14. Slide 14: Net Sales Forecast by Product Category

    SUBJECT TO FRE 408, STATE LAW EQUIVALENTS Net Sales Forecast by Product Category (1) (1) Specialty Brands Net Sales ($ in millions) Specialty Generics Net Sales ($ in millions) $1,800 $1,800 40% 35% $1,600 $1,600 35% 32% $1,400 $1,400 29% 30% $775 $715 $753 $1,200 $796 $728 $1,200 24% 24% 25% $1,000

  15. Slide 15: Consolidated Projections Overview & Key Assumptions

    SUBJECT TO FRE 408, STATE LAW EQUIVALENTS Consolidated Projections Overview & Key Assumptions › Key strategic priorities include: − Optimize resource allocation efforts towards Critical Care opportunities to strengthen clinical pipeline aligned with differentiated capabilities, while sustaining the

  16. Slide 16: Summary Preliminary Consolidated Projections

    SUBJECT TO FRE 408, STATE LAW EQUIVALENTS Summary Preliminary Consolidated Projections ($ in millions) 2021E 2022E 2023E 2024E 2025E Net Sales Specialty Brands $ 1, 707 $ 1, 571 $ 1, 558 $ 1, 588 $ 1, 607 Specialty Generics 680 720 800 918 916 Consolidated Net Sales $ 2, 387 $ 2, 290 $ 2, 358 $ 2, 5

  17. Slide 17: Illustrative Emergence Sources & Uses

    SUBJECT TO FRE 408, STATE LAW EQUIVALENTS Illustrative Emergence Sources & Uses • The following illustrative emergence sources and uses are based on an emergence at the end of September 2021 • Note that these estimates exclude potential CARES Act refunds given the uncertainty of timing related revie

  18. Slide 18: Consolidated EBITDA Bridge From Prior Plan

    SUBJECT TO FRE 408, STATE LAW EQUIVALENTS Consolidated EBITDA Bridge From Prior Plan • Cumulative Consolidated EBITDA, when compared to the prior plan, is projected to be above prior plan • Margin changes driven by exclusion of Terlivaz and revised assumptions across other Brands and Generics produc

  19. Slide 19: 2020 and 2021 KEIP Performance Measures

    SUBJECT TO FRE 408, STATE LAW EQUIVALENTS 2020 and 2021 KEIP Performance Measures $ in millions Notes (1) Preliminary and unaudited. (2),(7) Performance Measures - 2020 (2) Consistent with prior year practices, the performance measures used for compensation Actuals purposes include non-GAAP financia

  20. Slide 20: Bridges of GAAP Financial Measures to non-GAAP Performance Measures

    SUBJECT TO FRE 408, STATE LAW EQUIVALENTS Bridges of GAAP Financial Measures to non-GAAP Performance Measures Adj. Operating Cash Flow ($ in millions) 2020 Full (1) H1A Q3A 2020 Q4A Operating Cash Flow (GAAP) $ 225 $ 70 $ 204 $ 499 Separation Cost 42 33 18 93 Reorganization Advisor Fees - - 51 51 CA

Mallinckrodt — Corporate Update (March 2021) on 6ix